Pharsight

Drugs that contain Lemborexant

1. Dayvigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2025
M(M-293) Apr 20, 2026

NCE-1 date: 07 April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

Family Patents